Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Emerging Therapies
Oncology Pipeline Full, and Not Just with Immunotherapies
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
September 2015, Vol 6, No 8
Clinicians will soon have more targeted therapies at their disposal, including drugs with novel mechanisms of action.
Read Article
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
Emerging Therapies
,
Personalized Medicine
August 2015, Vol 6, No 7
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in
Nature Medicine
.
Read Article
GADOLIN Trial: Obinutuzumab an Effective Treatment for Indolent Lymphoma
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
August 2015, Vol 6, No 7
Chicago, IL—The results of the phase 3 GADOLIN trial provide the first proof of efficacy for obinutuzumab (Gazyva) in patients with indolent non-Hodgkin lymphoma (NHL). Obinutuzumab added to standard bendamustine (Treanda) chemotherapy almost doubled progression-free survival (PFS) in patients with rituximab (Rituximab)-refractory indolent lymphoma—the median PFS was 29.2 months with obinutuzumab plus bendamustine versus 14 months with bendamustine alone.
Read Article
2014 Oncology Pipeline Looks Impressive
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
August 2014, Vol 5, No 6
The cancer drug pipeline continues to boast many new therapies, reinforcing the recent trends of new and improved monoclonal antibodies and other classes of targeted therapies for different types of tumors.
Read Article
Hematologic Drug Pipeline Boasts Novel Approaches
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Novel options for the treatment of patients with hematologic conditions are in the pharmaceutical pipeline, with many drugs showing promising results. Here is a look at key studies presented at the 2013 American Society of Hematology annual meeting.
Read Article
Idelalisib and Ibrutinib 2 Promising B-Cell Receptor–Signaling Inhibitors for B-Cell Malignancies
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
October 2013, Vol 4, No 8
Read Article
Emerging Therapies and New Approaches in the “Double-Refractory” Setting in Myeloma
By
Wayne Kuznar
Drug Updates
,
Emerging Therapies
,
Personalized Medicine
September 2013, Vol 4, No 7
Chicago, IL—Advances in the understanding of the biology of multiple myeloma and the identification of new drugs have resulted in improved management of myeloma, including for disease refractory to the recent proteasome inhibitors and immunomodulatory agents that have been added to the treatment of patients with myeloma.
Read Article
Page 6 of 6
1
2
3
4
5
6
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma